Cipher Pharmaceuticals, a specialty pharmaceutical company with a focus on dermatology, has announced several changes to its Board of Directors.
Gerald P. McDole, William D. Claypool, MD, Renee P. Tannenbaum and Rosemary A. Crane will step down from the Board effective immediately. Incumbent directors Stephen R. Wiseman, Stefan Aigner, MD, Thomas G. Wellner and John D. Mull, MD, will be joined on the Board by:
- Mark Beaudet, co-founder of Paladin Labs, which was acquired by Endo International in 2014 for approximately $3.0 billion. Beaudet served as a member of its Board of Directors and as the company’s vice president of sales and marketing until 2011 when he became president and chief executive officer. Following Endo’s acquisition of Paladin, he joined the Endo International executive leadership team and continued to lead the Paladin team until his departure in June 2016.
- Christian Godin, head of equities at Montrusco Bolton Investments and member of its Board of Directors. He is also a member of the Management Committee of Montrusco, a Montreal-based investment firm that has approximately $6.0 billion in assets under management.
- Harold Wolkin, investment banker and financial analyst with over 30 years of experience. He joined BMO Nesbitt Burns as a senior research analyst in 1983 and went on to serve as managing director in the Diversified Industries Group of BMO Capital Markets until January 2008. Most recently, Wolkin served as executive vice president and head of investment banking for Dundee Capital Markets.
“Cipher is extremely grateful to the outgoing directors for their conscientious service to the Board and wish them continued success in their professional endeavours,” said Stephen Wiseman, chairman of the Special Committee of the Board.
